Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accounts Payables (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Accounts Payables for 15 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 21.88% to $14.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.3 million, a 21.88% increase, with the full-year FY2025 number at $10.6 million, up 2.78% from a year prior.
  • Accounts Payables was $14.3 million for Q4 2025 at Aytu Biopharma, up from $12.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $19.3 million in Q2 2021 to a low of $9.4 million in Q3 2021.
  • A 5-year average of $12.6 million and a median of $12.0 million in 2025 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 1281.89% in 2021, then tumbled 42.94% in 2022.
  • Aytu Biopharma's Accounts Payables stood at $15.6 million in 2021, then tumbled by 32.2% to $10.6 million in 2022, then dropped by 1.01% to $10.5 million in 2023, then rose by 11.71% to $11.7 million in 2024, then increased by 21.88% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Accounts Payables are $14.3 million (Q4 2025), $12.3 million (Q3 2025), and $10.6 million (Q2 2025).